DE60036697D1 - Uteroglobin zur behandlung von iga vermittelten autoimmunerkrankungen - Google Patents

Uteroglobin zur behandlung von iga vermittelten autoimmunerkrankungen

Info

Publication number
DE60036697D1
DE60036697D1 DE60036697T DE60036697T DE60036697D1 DE 60036697 D1 DE60036697 D1 DE 60036697D1 DE 60036697 T DE60036697 T DE 60036697T DE 60036697 T DE60036697 T DE 60036697T DE 60036697 D1 DE60036697 D1 DE 60036697D1
Authority
DE
Germany
Prior art keywords
iga
uteroglobin
treatment
autoimmune diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036697T
Other languages
English (en)
Inventor
Anil B Mukherjee
Feng Zheng
Zhongjian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60036697D1 publication Critical patent/DE60036697D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
DE60036697T 1999-04-21 2000-04-13 Uteroglobin zur behandlung von iga vermittelten autoimmunerkrankungen Expired - Lifetime DE60036697D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13043499P 1999-04-21 1999-04-21
PCT/US2000/009979 WO2000062795A2 (en) 1999-04-21 2000-04-13 UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS

Publications (1)

Publication Number Publication Date
DE60036697D1 true DE60036697D1 (de) 2007-11-22

Family

ID=22444672

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036697T Expired - Lifetime DE60036697D1 (de) 1999-04-21 2000-04-13 Uteroglobin zur behandlung von iga vermittelten autoimmunerkrankungen

Country Status (8)

Country Link
US (1) US8084415B2 (de)
EP (1) EP1173195B1 (de)
AT (1) ATE375167T1 (de)
AU (1) AU779281B2 (de)
CA (1) CA2370738C (de)
DE (1) DE60036697D1 (de)
NZ (1) NZ515588A (de)
WO (1) WO2000062795A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5836700A (en) * 1999-06-01 2000-12-18 Patrick T. Prendergast Peptides for therapeutic use
CA2699052A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008310074A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of the peptide thymosin beta 4 alone or in combination with cecropin A as a therapeutic agent
WO2009033707A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US9339526B2 (en) 2011-01-17 2016-05-17 University Of Manitoba Methods for treating disorders that involve immunoglobulin A
US9598733B2 (en) 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
WO2014169294A1 (en) 2013-04-12 2014-10-16 The Trustees Of Columbia University In The City Of New York Mutations in dstyk cause dominant urinary tract malformations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0682524T3 (da) * 1993-02-02 2002-01-28 Xoma Technology Ltd Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US6255281B1 (en) * 1997-05-28 2001-07-03 Claragen, Inc. And U.S. Government Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
EP1235846A4 (de) * 1999-11-04 2004-07-14 Human Genome Sciences Inc Uteroglubinartige polynukleotide, polypeptide und antikörper

Also Published As

Publication number Publication date
WO2000062795A3 (en) 2001-09-13
US8084415B2 (en) 2011-12-27
ATE375167T1 (de) 2007-10-15
AU4348000A (en) 2000-11-02
US20090029908A1 (en) 2009-01-29
WO2000062795A2 (en) 2000-10-26
EP1173195A2 (de) 2002-01-23
CA2370738C (en) 2011-08-09
WO2000062795A9 (en) 2001-10-04
CA2370738A1 (en) 2000-10-26
NZ515588A (en) 2003-10-31
AU779281B2 (en) 2005-01-13
EP1173195B1 (de) 2007-10-10

Similar Documents

Publication Publication Date Title
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
DE60329990D1 (de) Mitotische kinesin-hemmer
ATE324908T1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
EP0831832A4 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ATE524195T1 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
BR9914735A (pt) Processo para tratamento de sépsia
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE419857T1 (de) Verwendung von abführmittel zur behandlung des reizdarmsyndroms
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE375167T1 (de) Uteroglobin zur behandlung von iga vermittelten autoimmunerkrankungen
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE239467T1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
WO2004024089A3 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing

Legal Events

Date Code Title Description
8332 No legal effect for de